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Aim: Fecal and urinary incontinence are devastating consequences of obstetric-
related perineal injury. The aim of the present study is to determine acceptability to 
parous women of autologous cell-based therapy for fecal and urinary incontinence 
that arises due to pelvic diaphragm tearing during vaginal childbirth. Materials & 
methods: A multiple choice questionnaire survey was offered to 76 parous women 
at the Maternity Unit, University College Hospital, London, UK. Seventy completed 
questionnaires – response rate: 92%. Results: In total, 84% of women indicated a 
willingness to accept autologous cell-based therapy for obstetric injury-induced 
incontinence rather than surgery. Conclusion: These observational data provide an 
indication of likely acceptance of autologous cell-based therapies for birth injury 
incontinence and will help with designing new therapeutic approaches.
First draft submitted: 10 August 2015; Accepted for publication: 18 December 2015; 
Published online: 15 February 2016
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Fecal incontinence ([FI] urge and accidental 
bowel leakage) and stress urinary inconti-
nence (SUI) are distressing and life-limiting 
conditions that affect women after child-
birth. Obstetric trauma to muscles, nerves, 
or connective tissues of the pelvic diaphragm 
is the commonest cause of FI [1] and occurs 
in 10–15% of vaginal deliveries [2,3]. Thera-
peutic strategies to address these symptoms 
are generally not curative – surgical repair 
is associated with poor long-term out-
comes [4–6] and conservative therapies are 
primarily aimed at palliation. The majority 
of those patients will develop incontinence 
symptoms many years after childbirth. 
Recent preclinical and early-stage clinical 
studies have indicated cell-based strategies 
using autologous cells offer the potential to 
regenerate damaged urethral [7,8] and anal [9] 
sphincter muscle to cure SUI and FI.
Compounding this problem, parous 
women who present with pelvic floor tears 
and prolapse sustained during childbirth 
have a poor understanding of long-term 
healthcare options for obstetric injury risk. 
It is unclear to what extent women would 
be prepared to undertake specialist assess-
ment and cell-based treatment for symp-
toms of SUI and FI. Such information is 
fundamental to the design and implemen-
tation of studies investigating the develop-
ment of cell-based therapies. The primary 
objective of the current study is to establish 
the opinions of parous women for autolo-
gous cell-based therapy that may provide 
prophylactic and curative solutions for FI 
and SUI.
A diverse range of therapeutic interven-
tions that are selected based upon the sever-
ity of FI or SUI are currently available. 
These include biofeedback (e.g., pelvic floor 
exercises) [10,11], surgery to repair sphincters 
involving muscle transfer procedures [12], 
transplantation of artificial sphincters [13–15] 
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or muscle with stimulating electrodes [16,17], sacral 
nerve stimulation [18–20], vaginal slings [21,22], and/or 
recommendation of elective caesarean sections for 
future pregnancies [23] in high-risk cases (due to pre-
vious traumatic damage to the pelvic floor). Intrac-
table SUI and FI are typically managed with catheter 
placement and permanent colostomy, respectively. 
Thorough pelvic examinations [24] following vaginal 
deliveries can aid early diagnosis of risk of SUI and FI.
Many of the therapies currently being developed 
for SUI and FI are designed to offer curative options 
that can supersede existing clinical interventions that 
may only allow a measure of symptom control. In the 
present study, an emerging cell-based therapy con-
sisting of autologous skeletal myoblasts attached to 
biodegradable microspheres was explained to parous 
women as a potential curative treatment option for 
SUI and FI.
The premise for the present research is supported 
by a study demonstrating the technical feasibility of 
delivering autologous skeletal myoblasts as a potential 
treatment for FI [9]. In that uncontrolled pilot study, 
cells harvested from a pectoralis muscle biopsy were 
injected into the external anal sphincter defect using 
direct ultrasound guidance. Data at 1 year indicated 
a decrease in the Wexner score and patients reported 
improved quality of life but anorectal physiology 
(anal squeeze and resting pressure) was not improved. 
A recent 5-year follow-up observational study [25] of 
the same group suggests a general increase in anal 
squeeze and resting pressure at 5 years compared with 
baseline. While this remains an uncontrolled study it 
indicates the potential benefit of cell-based therapy 
for FI.
In the present study we developed a multiple 
choice questionnaire to assess whether or not pri-
miparous and multiparous women would consider 
complex specialist evaluation and treatment follow-
ing perineal birth trauma. The purpose of the ques-
tionnaire was as a tool to provide an initial observa-
tion of women’s opinions on cell-based incontinence 
therapy. The use of biomaterials to deliver autologous 
cells to treat FI and SUI was described in lay terms 
to parous women using diagrams. Data derived 
from the observational questionnaire will help with 
the design of new therapeutic strategies as well as 
forming the basis for more in-depth questionnaires 
specifically outlining the detail of cell-based thera-
pies for birth injury-related FI and SUI. Here, we 
examined whether women’s beliefs/views to undergo 
enhanced evaluation and cell-based therapy related 
to the presence of symptoms of incontinence. The 
key finding in this observational study revealed that 
the majority of women were willing to accept an 
autologous cell-based therapy for obstetric injury-
induced incontinence. This finding correlated with 
worry about developing FI and SUI later in life as 
well as acceptance for assessment of obstetric risk. 
We therefore concluded that from the stand-point 
of parous women, there is a strong case for develop-
ment of autologous cell-based therapeutic interven-
tions as prophylactic or treatment measures against 
obstetric-injury related FI and SUI.
Patients & methods
Patients & study design
A questionnaire survey of women (n = 76 with n = 70 
respondents) attending the Maternity Unit at Uni-
versity College Hospital (London, UK) for postna-
tal care was undertaken. All women who provided 
informed consent to participate had previously had 
children in the unit and the cohort included a mixed 
group with various degrees of obstetric injuries. To 
be eligible for the study, it was necessary for the 
women involved to have had a vaginal delivery and 
be between the ages of 16 and 50 years. Participants 
were approached and invited to complete a question-
naire structured to determine their views and prefer-
ences with regard to specialist assessment and treat-
ment with an autologous cell-based therapy to treat 
incontinence. The women verbally agreed to this 
questionnaire-based participation. We did not obtain 
informed formal consent as this was a survey ques-
tionnaire to obtain opinions unrelated to individual 
therapy decisions. The multiple choice questionnaire 
is shown as Supplementary Data.
Questionnaire analysis
The multiple choice questionnaire (see Supplemen-
tary Data) was presented to patients with explana-
tions (delivered verbally by the interviewer) of the 
cell-based therapy aimed at treating obstetric-injury 
induced SUI and FI. The questionnaire was struc-
tured as a series of questions that established the age 
range, parity, continence, willingness to opt for assess-
ment of obstetric risk, feelings about developing SUI 
and FI later in life, willingness to consider cell-based 
therapy for incontinence, thoughts regarding tim-
ing of treatment, and questions and comments from 
women about the novel therapy. Correlations between 
responses, for example, willingness to be assessed for 
obstetric risk and continence were analyzed. This was 
primarily an observational study. The responses to 
the query for willingness to opt for cell-based therapy 
were interrogated with follow-up questions involving 
a scoring scale of 1–10. We classified responses 7–10 
as “willing to be treated,” responses 4–6 as “unsure 
about treatment,” responses 0–3 as “unwilling to 
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have treatment.” Statistical significance between data 
trends was determined using SPSS (version 22 for 
Windows. Armonk NY, USA).
Results
Demographics
The modal age group was 26–35 years (49%; 34 out 
of 70), with 40% (28 out of 70) aged 36–45 years, 7% 
(five out of 70) aged 20–25 years old, and 4% (three 
out of 70) aged over 46 years. The majority of women 
were uniparous (67%; 47 out of 70) and 33% (23 out 
of 70) were multiparous. Within those groups, mul-
tiparous women in the 20–25 years and 26–35 years 
subgroups had less than four children. The majority 
of multiparous women in the 36–45 years age range 
had two children and those who were more than 
46 years old tended to have more than two children.
Symptoms
In total, 21% (15 out of 70) of the cohort were some-
times faecally incontinent at the time of completion of 
the questionnaire and 7% presented with fecal incon-
tinence (five out of 70). The ability of women to con-
trol their bowels did not correlate with their age, their 
parity, or the period of time after deliveries.
Willingness to be assessed for obstetric risk
The majority of the cohort (90%; 63 out of 70) 
expressed a desire to be assessed for risk of obstetric 
injury before giving birth (Figure 1). This was inde-
pendent of their current ability to control their bow-
els. One woman out of 63 (2%) within the group that 
accepted assessment of obstetric risk was incontinent, 
13 out 63 (21%) were sometimes incontinent, and 
remaining 49 (out of 63: 78%) were continent. Only 
two women (out of 70) did not want to be assessed 
for obstetric risk. There was no significant relation-
ship (p = 0.26) between willingness to be assessed for 
obstetric risk and continence.
Feelings about developing stress urinary 
& fecal incontinence later in life
A greater percentage of the cohort were worried about 
developing SUI and FI later in life (80%; 56 out of 70) 
than those who were unsure (6%; four out of 70) or 
not worried (14%; ten out of 70) (Figure 2). Within the 
group of women who were worried, 14 women (14 out of 
56; 25%) were sometimes unable to control bowels, five 
(five out of 56; 9%) were incontinent, and the remain-
ing women (37 out of 56) were continent (Figure 2). 
There was a significant correlation (p = 0.0001) between 
current symptoms of incontinence and worry about 
developing SUI and FI later in life.
Willingness to accept cell-based therapy for 
incontinence
In total, 79% (55 out of 70) of the cohort were willing 
to opt for cell-based therapy to reduce incontinence 
later in life (Figure 3A). The majority of this group 
(49 out of 55) was worried about developing SUI and 
FI later in life. Only two women (out of 70) – one 
of whom was not worried about developing inconti-
Figure 1. Correlations between willingness to be assessed for obstetric risk correlated and incontinence. 
Assessments for obstetric risk were acceptable for women whether or not they presented fecal incontinence. 
Percentages are a proportion of the cohort consisting of 70 parous women.
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nence – indicated that they would not opt for a novel 
cell-based therapy. In total, 84% (59 out of 70) of 
the cohort indicated willingness for cell therapy over 
symptom control options and 1% (one out of 70) 
were unwilling, with 14% (ten out of 70) unsure 
(Figure 3B).
A further details of cell therapy explored was with 
regard to having autologous cells attached to biode-
gradable microspheres placed in the urethral and anal 
sphincters. A slightly lower proportion of women (71%; 
50 out of 70) were willing to consider such treatment 
as an alternative to a surgical operation, 23% (16 out 
of 70) were unsure and 4% (three out of 70) would 
not consider it, and 1% (one out of 70) may or may 
not consider autologous cell-based therapy instead of a 
surgical operation (Figure 3C). There was a significant 
correlation (p = 0.0002) between worry of developing 
incontinence later in life and willingness to consider 
autologous cell-based therapy. Willingness to accept 
autologous cell-based therapy over symptom control 
correlated significantly (p = 0.0001) with worry about 
developing SUI and FI. Lack of acceptance of autolo-
gous cell-based therapy in the absence of incontinence 
symptoms was also significant (p = 0.0001). Taken 
together, these data demonstrated that sequential, 
follow-up inquiry potentially highlighted a distinct 
subset that was willing to adopt a novel autologous 
cell-based therapy for SUI and FI.
More than half of the cohort (51%; 36 out of 70) 
were willing to opt for treatment in the absence of SUI 
and FI symptoms. However, 37% (26 out of 70) were 
unsure, and 11% (eight out of 70) would not opt for 
novel treatments in the absence of SUI and FI symp-
toms (Figure 4A). By contrast, when women were asked 
if they would accept treatment if presenting with symp-
toms of FI (Figure 4B), the majority (89%; 62 out of 
70) scored yes and only one patient indicated that she 
would not like the novel therapy in such circumstances. 
Questions relating to administration of the cell-based 
therapy correlated well to responses for willingness to 
accept novel therapy for SUI and FI. The majority of 
women who would consent to a muscle biopsy for col-
lection of muscle cells (Figure 5A) for the novel treat-
ment (61%; 43 out of 70), also indicated that they 
would opt for autologous cell therapy for SUI and FI 
(91%; 39 out of 43). Approximately one third of the 
cohort (31%; 22 out of 70) were unsure about allowing 
a muscle biopsy, but within that group, 45% (ten out 22) 
had previously been unsure about opting for the novel 
therapy over symptom control. There were significant 
levels (p = 0.00009) of uncertainty within the cohort for 
allowing a muscle biopsy. In total, 64% (45 out of 70) of 
parous women would participate in a clinical trial and 
30% (21 out of 70) were unsure (Figure 5B).
Timing of treatment
The most popular preference for when to initiate 
treatment was immediately after childbirth (31%: 22 
out of 70) (Figure 6). A subgroup of 18 women (26%; 
18 out of 70) would opt for therapy before childbirth, 
Figure 2. Parous women were worried about developing incontinence later in life. Women were worried about 
developing SUI and FI later in life regardless of ability to control bowels. Percentages are a proportion of the 
cohort consisting of 70 parous women. 
FI: Fecal incontinence; SUI: Stress urinary incontinence.
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Figure 3. Parous women accept a cell-based therapy for incontinence. The majority of women who were willing to 
opt for cell-based therapy for SUI and FI were worried about developing incontinence later in life (A). The greatest 
proportion of the cohort (n = 70) were willing to opt for the therapy as an alternative to symptom control (B) or a 
surgical operation (C). Percentages are a proportion of the cohort consisting of 70 parous women. 
FI: Fecal incontinence; SUI: Stress urinary incontinence.
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20% of the cohort (14 out of 70) preferred treat-
ment 6 months after childbirth. The least popular 
preference was for initiation of treatment more than 
6 months after childbirth (9%; six out of 70). A pro-
portion of the cohort (10%; eight out of 70) were par-
tial to multiple treatment periods, for example, before, 
immediately after, 6 months after, and more than 
6 months after childbirth or before and immediately 
after childbirth. There were no convincing trends 
between willingness to opt for the novel therapy or 
feelings about developing SUI and FI later in life and 
individual options for when to initiate therapy.
Figure 4. Acceptance of the cell-based therapy in the absence of incontinence symptoms was less avid than in the 
presence of those symptoms. The percentage of parous women who were willing to accept cell-based therapy 
in the absence of SUI and FI symptoms was similar to the proportion who was unsure (A). The majority of the 
cohort accepted the cell therapy in the presence of FI symptoms (B). Percentages are a proportion of the cohort 
consisting of 70 parous women. 
FI: Fecal incontinence; SUI: Stress urinary incontinence.
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Questions & comments from women about the 
cell-based therapy
The questionnaire included a free text option and 
the majority of questions or comments related to 
risks involved with the novel therapy. Less fre-
quently there were questions about the efficacy 
of the therapy and least often asked were practi-
cal questions about the practicalities of timings of 
treatment and recovery. There were individual com-
ments about ethics of cell therapy and the need for 
prevention rather than cure of traumatic obstetric 
injuries.
Figure 5. Parous women were willing to contribute autologous muscle cells for cell-base therapy and participate 
in related clinical trials. The majority of the cohort was willing to contribute a muscle biopsy for harvesting 
autologous cells (A) and they were also willing to participate in a clinical trial of this type of therapy (B). 
Percentages are a proportion of the cohort consisting of 70 parous women.
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Discussion
Principal findings
Acceptance levels were high, with four out of every 
five women (from the cohort of 70 women) amenable 
to an autologous cell-based therapeutic modality as 
a potentially curative treatment for obstetric injury-
induced SUI and FI. This strong trend in approval 
for a cell-based therapy as opposed to surgery, cor-
related with feelings of worry (83%; 49 out of 59 
of women were worried about developing SUI or FI 
later in life) of women as well as willingness to con-
sider the novel therapy over surgery (71%: 50 out of 
70). This subgroup of women was also worried about 
developing SUI and FI later in life. Similarly, willing-
ness to undergo assessment for obstetric injury risk was 
a prominent response (88% were willing) that could 
be associated with agreement for the autologous cell-
based therapy. These data suggest that fear of latent 
development of SUI and FI is an important underlying 
factor in deciding to undergo specialist assessment and 
complex therapy for these symptoms.
Uncertainty about muscle biopsy may be due to fear 
of pain, scarring, infections, and long-term impair-
ment of muscle functions following removal of the 
tissue. At present, information about the size of the 
muscle biopsy required for collection of cells, protocols 
for acquiring the biopsy, and follow-up care to mini-
mize scarring and trauma to the harvest site are evolv-
ing. The results of this questionnaire study suggest that 
revealing details about the requirements for receiving 
the cell-based therapy may distinguish groups who are 
genuinely interested in its clinical application from 
those who may only support the concept of a curative 
therapy for SUI and FI.
Individual options for when to initiate therapy were 
not influenced by willingness to opt for the novel ther-
apy or feelings about developing SUI and FI later in 
life. These data indicate that questions related to when 
to initiate treatment may be abstract at this early pre-
clinical stage and need a clearer evidence base to help 
women indicate firm preferences for timing of therapy.
Strengths & limitations
The main strength of the present study was the clear 
correlation between acceptability of the autologous 
cell-based therapy and worry about developing FI and 
SUI later in life. These data provide a basis from which 
patients’ compliance for future therapies can be antici-
pated and quantified. The associated limitation, how-
ever, was the lack of a strong evidence base describing 
the application and clinical benefits of the cell-based 
therapy. This drawback was reflected in questions and 
comments that were put forward by a number of women 
who participated in the survey. This limitation will be 
addressed with ongoing clinical and preclinical studies 
from our group and other groups that involve testing 
the efficacy of different cell-based therapeutic strategies. 
A key asset of this study is that women indicated little 
awareness of assessment for obstetric risk factors – the 
majority signposted their interest in receiving antenatal 
evaluation for risk of obstetric injury. This response may 
lead to further studies investigating current practice in 
ante- and post-natal care for women in the UK. Increas-
ing the size of the cohort would allow a more reliable 
estimation of the primary concerns of parous women 
with regard to reproductive health, as well as allow bet-
ter study of correlation between treatment acceptance 
and age, parity, and current bowel/bladder control.
Comparison with existing literature
Studies investigating patients’ views on prospective 
therapies for obstetric injury dependent stress uri-
nary and fecal incontinence are scarce. Cohort studies 
describing treatment preferences for urinary inconti-
nence have previously been reported [26–28]. Those, 
however, present therapeutic modalities that are vali-
dated and clinically available. One study elicited pref-
erences for urinary continence treatment for residents 
in long-term care from their proxy care providers [27]. 
The preferred treatment options were the noninvasive 
strategies, prompted voiding and diapers rather than 
the invasive strategies, indwelling catheters and elec-
trical stimulation. Older adults preferred therapies 
directed at the underlying causes of urinary inconti-
nence, in other words, drug medication and electrical 
stimulation. That survey is comparable to the main 
section of the present study concerned with establish-
ing women’s views on a cell-based therapy as opposed 
to conventional surgical procedures. In the current 
study there was no correlation between age and treat-
ment preference – the majority of parous women in the 
20–25-year, 26–35-year, and 36–45-year age ranges 
chose the option of a cell-based therapy rather than 
surgery.
The lack of awareness of procedures for assessment 
of obstetric risk and the impact of obstetric injuries 
encountered in the present study highlights a critical 
need in women’s reproductive health provision in the 
UK. A previous study [26] described a similar issue in 
Boston (MA, USA) within a community of black, His-
panic, and white adults. More than 40% of women 
in the cohort (5506 adults) and approximately 20% of 
men with weekly incontinence reported that they had 
never sought care for this condition. From those who 
pursued treatment, 60% received it, but half of those 
continued to experience daily leakage. A conclusion of 
the study was that the majority of incontinent adults in 
the cohort who sought treatment did not believe that 
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it was provided as symptoms continued. Apathy from 
healthcare providers with regard to efficacy of thera-
pies was cited as an underlying cause for unsatisfactory 
therapy for urinary incontinence.
Implications for clinicians & policy-makers
This study has drawn together a number of distinct 
strands of inquiry concerning women’s acceptance 
of therapy for SUI and FI. Responses indicated the 
importance of raising awareness of obstetric injury 
risk and the occurrence of incontinence due to those 
injuries. Procedures to integrate screening procedures 
for assessment of obstetric risk, treatment strategies for 
prospective obstetric injuries, and measures for pre-
vention of obstetric injuries into current antenatal care 
programs is a challenge for hard-pressed services.
Unanswered questions & future research
Future studies of invasive incontinence therapies should 
include detailed information on the administration of 
the new types of therapy and assessment of patients’ 
willingness to undergo such therapies. Separate studies 
to investigate knowledge gaps in populations of parous 
women regarding existing and possible options at both 
ante- and post-natal stages would also be informative.
Conclusion
The present study demonstrates a clear trend in 
acceptance for autologous cell-based therapy for SUI 
and FI. The correlation of fear of developing SUI and 
FI and general agreement to receive assessment for 
risk of obstetric injury with compliance for a novel 
therapy indicates the importance of addressing this 
issue honestly and empathically. The clinical requi-
site for enhanced therapy to reduce the incidence of 
late-onset SUI and FI that arise due to obstetric inju-
ries is stressed. Furthermore, addressing this aspect 
of human reproductive morbidity will allow reforms 
in the quality and consistency of clinical and physi-
ological care provided to parous women. Regenera-
tive and/or prophylactic therapy for obstetric injuries 
can complement campaigns to raise awareness of 
ante- and postnatal care that may in turn destigma-
tize these life-altering symptoms. Prospective stud-
ies that follow-on from the work described here will 
involve more in-depth evaluations of women’s views 
on autologous cell-based therapy once they have 
been provided with more information regarding this 
treatment option.
Future perspective
The evolution of therapy for obstetric-related FI and 
SUI is critically dependent on accurate assessment and 
quantification of patient needs in parallel with develop-
ment of therapies. Over the next 5–10 years, it is likely 
that new therapeutic strategies based on autologous 
skeletal myoblasts alone or attached to biodegradable 
materials will advance to human clinical trials. The 
evidence base for ethical approval of those trials will 
include validated questionnaires from parous women 
responding to the likely risk/benefit based on the out-
come of preclinical studies. Furthermore, standardized 
clinical assessment of women’s risk for obstetric injuries 
will inform this clinical work and drive development 
of pre-emptive strategies for managing perineal tears. 
Therapeutic tools such as those outlined in the current 
study may allow women greater control and longevity in 
their reproductive life span and health.
Executive summary
Need for women’s opinions on pre-emptive autologous cell therapy for fecal & stress urinary 
incontinence due to childbirth injuries
•	 Parous women who present with pelvic floor tears and prolapse sustained during childbirth have a poor 
understanding of long-term healthcare options for obstetric injury risk.
•	 Addressing the underlying cause of fecal incontinence (FI) and stress urinary incontinence (SUI) at an early 
stage, before symptoms have emerged, may be key to preventing onset later in life. Women’s perception of 
this type of pre-emptive approach can accelerate development of therapies for FI and SUI.
Response of parous women to novel, developing autologous cell therapy for FI & SUI
•	 A multiple choice questionnaire was developed to assess whether or not primiparous and multiparous women 
would consider complex specialist evaluation and treatment following perineal birth trauma.
•	 Beliefs/views to undergo enhanced evaluation and cell-based therapy related to the presence of symptoms of 
incontinence were also investigated.
•	 The majority of women were willing to accept an autologous cell-based therapy for obstetric injury induced 
incontinence.
Usefulness of acquiring women’s views on developing therapies for FI & SUI
•	 Addressing the impact of perineal injury will allow reforms in the quality and consistency of clinical and 
physiological care provided to parous women.
•	 Regenerative and/or prophylactic therapy for obstetric injuries can complement campaigns to raise awareness 
of ante- and post-natal care that may in turn destigmatize these life-altering symptoms.
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